Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 May 1;111(9):4463-70.
doi: 10.1182/blood-2007-08-105759. Epub 2008 Feb 21.

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

Nathalie Mourad  1 , Nicolas Mounier, Josette Brière, Emmanuel Raffoux, Alain Delmer, Alfred Feller, Chris J L M Meijer, Jean-François Emile, Réda Bouabdallah, André Bosly, Jacques Diebold, Corinne Haioun, Bertrand Coiffier, Christian Gisselbrecht, Philippe Gaulard; Groupe d'Etude des Lymphomes de l'Adulte
Collaborators, Affiliations
Randomized Controlled Trial

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

Nathalie Mourad et al. Blood. .

Abstract

To evaluate the prognostic significance of clinicobiologic and pathological features in angioimmunoblastic T-cell lymphoma (AITL), 157 AITL patients were retrieved from the GELA LNH87-LNH93 randomized clinical trials. One hundred forty-seven patients received a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimen with intensified courses in half of them. Histologically, 41 cases were classified as "rich in large cells" and 116 as "classic" (including 19 rich in epithelioid cells, 14 rich in clear cells, and 4 with hyperplastic germinal centers). Sixty-two cases were scored for CD10 and CXCL13 expression according to the abundance of positive lymphoid cells. Median age was 62 years, with 81% advanced stage, 72% B symptoms, 65% anemia, 50% hypergammaglobulinemia, and 66% elevated LDH. Overall 7-year survival was 30%. In multivariate analysis, only male sex (P = .004), mediastinal lymphadenopathy (P = .041), and anemia (P = .042) adversely affected overall survival. Increase in large cells and high level of CD10 and CXCL13 did not affect survival. Intensive regimen did not improve survival. In conclusion, AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors. It portends a poor prognosis even when treated intensively. However, AITL is not always lethal with 30% of patients alive at 7 years.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histopathologic spectrum of AITL and patterns of CXCL13 expression. Panels A-E illustrate the large spectrum of angioimmunoblastic lymphoma. Panels F,G illustrate CXCL13 immunostaining patterns: (A) classic-type, (B) rich in large cells, (C) with hyperplastic germinal centers, (D) rich in clear cells, (E) rich in epithelioid cells (hematoxylin eosin stain); (F) score 1, (G) score 2, and (H) score 3. Images were captured by a Zeiss microscope (Carl Zeiss, Heidelberg, Germany); original magnifications ×25 (C) and ×250 (A,B,D-H). The different morphologic subtypes and the level of CXCL13 expression did not influence survival.
Figure 2
Figure 2
Survival of the 156 patients with angioimmunoblastic T-cell lymphoma. Overall survival (A) and event-free survival (B).
Figure 3
Figure 3
Overall survival of angioimmunoblastic T-cell lymphoma patients. Overall survival figures according to IPI (A) and PIT (B) scores are shown.
See this image and copyright information in PMC

References

    1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon, France: IARC Press; 2001. World Health Organization classification of tumours: Pathology and genetics, tumours of haematopoietic and lymphoid tissues.
    1. Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood. 1992;79:1789–1795. - PubMed
    1. Feller AC, Diebold J. Berlin Heidelberg, Germany: Springer-Verlag; 2004. Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas.
    1. Abruzzo LV, Schmidt K, Weiss LM, et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood. 1993;82:241–246. - PubMed
    1. Matsue K, Itoh M, Tsukuda K, Kokubo T, Hirose Y. Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. Int J Hematol. 1998;67:319–329. - PubMed

Publication types

MeSH terms